| Gold (I)–NHC complexes of antitumoral diarylimidazoles: Structures, cellular uptake routes and anticancer activities L Kaps, B Biersack, H Müller-Bunz, K Mahal, J Münzner, M Tacke, ... Journal of inorganic biochemistry 106 (1), 52-58, 2012 | 109 | 2012 |
| Effects of chrysin, apigenin, genistein and their homoleptic copper (II) complexes on the growth and metastatic potential of cancer cells C Spoerlein, K Mahal, H Schmidt, R Schobert Journal of inorganic biochemistry 127, 107-115, 2013 | 87 | 2013 |
| Ferrocene and (arene) ruthenium (II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action C Spoerlein-Guettler, K Mahal, R Schobert, B Biersack Journal of inorganic biochemistry 138, 64-72, 2014 | 54 | 2014 |
| Cancer selective metallocenedicarboxylates of the fungal cytotoxin Illudin M R Schobert, S Seibt, K Mahal, A Ahmad, B Biersack, ... Journal of medicinal chemistry 54 (18), 6177-6182, 2011 | 49 | 2011 |
| Improved anticancer and antiparasitic activity of new lawsone Mannich bases K Mahal, A Ahmad, F Schmitt, J Lockhauserbńumer, K Starz, R Pradhan, ... European journal of medicinal chemistry 126, 421-431, 2017 | 47 | 2017 |
| Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl) indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors K Mahal, B Biersack, S Schruefer, M Resch, R Ficner, R Schobert, ... European Journal of Medicinal Chemistry 118, 9-20, 2016 | 41 | 2016 |
| Effects of the Tumor‐Vasculature‐Disrupting Agent Verubulin and Two Heteroaryl Analogues on Cancer Cells, Endothelial Cells, and Blood Vessels K Mahal, M Resch, R Ficner, R Schobert, B Biersack, T Mueller ChemMedChem 9 (4), 847-854, 2014 | 40 | 2014 |
| New ferrocene modified lawsone Mannich bases with anti-proliferative activity against tumor cells A Ahmad, K Mahal, S Padhye, FH Sarkar, R Schobert, B Biersack Journal of Saudi Chemical Society 21 (1), 105-110, 2017 | 31 | 2017 |
| Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation K Mahal, B Biersack, H Caysa, R Schobert, T Mueller Investigational new drugs 33 (3), 541-554, 2015 | 27 | 2015 |
| Cellular Localisation of Antitumoral 6‐Alkyl Thymoquinones Revealed by an Alkyne–Azide Click Reaction and the Streptavidin–Biotin System K Effenberger‐Neidnicht, S Breyer, K Mahal, R Diestel, F Sasse, ... ChemBioChem 12 (8), 1237-1241, 2011 | 19 | 2011 |
| Biological evaluation of 4, 5-diarylimidazoles with hydroxamic acid appendages as novel dual mode anticancer agents K Mahal, S Schruefer, G Steinemann, F Rausch, R Schobert, B Biersack, ... Cancer chemotherapy and pharmacology 75 (4), 691-700, 2015 | 13 | 2015 |
| 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide–A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation K Mahal, P Kahlen, B Biersack, R Schobert Experimental cell research 336 (2), 263-275, 2015 | 9 | 2015 |
| New Oxazole-bridged combretastatin A-4 analogues as potential vascular-disrupting agents K Mahal, B Biersack, R Schobert Int. J. Clin. Pharmacol. Ther 51, 41-43, 2013 | 7 | 2013 |
| Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as visualised by intrinsic fluorescence K Effenberger-Neidnicht, S Breyer, K Mahal, F Sasse, R Schobert Cancer chemotherapy and pharmacology 69 (1), 85-90, 2012 | 5 | 2012 |
| 4, 5-Diarylimidazole derivatives as HDAC inhibitors M Höpfner, B Biersack, R Schobert, K Mahal US Patent 9,868,750, 2018 | 4 | 2018 |
| Role of JNK and NF-κB in mediating the effect of combretastatin A-4 and brimamin on endothelial and carcinoma cells K Mahal, A Ahmad, S Sethi, M Resch, R Ficner, FH Sarkar, R Schobert, ... Cellular Oncology 38 (6), 463-478, 2015 | 4 | 2015 |
| EACR-MRS conference on Seed and Soil: In Vivo Models of Metastasis IT Alves, N Cohen, PG Ersan, R Eyre, I Godet, D Holovanchuk, ... Clinical & experimental metastasis 34 (8), 449-456, 2017 | 1 | 2017 |
| Activity of a Doxorubicin Menthol Conjugate Against Circulating Epithelial Tumor Cells of Cancer Patients K Mahal, E Schill, S Breyer, U Pachmann, K Pachmann, R Schobert, ... Journal of Pharmaceutical Sciences and Pharmacology 1 (3), 233-236, 2014 | 1 | 2014 |
| UM Cure 2020: New therapies for uveal melanoma S Roman-Roman, MH Stern, S Alsafadi, MJ Jager, M Dogrusöz, ... Impact 2018 (2), 15-17, 2018 | | 2018 |
| CRISPR-generated BAP1 knockdown in uveal melanoma cell lines affects organotropism K Mahal, K Brooks, A Mandal, M Smith, N Dhomen, R Marais Cancer Research 77 (13 Supplement), 4844-4844, 2017 | | 2017 |
